Israel’s NeuroDerm has announced positive results for its Phase II trials of ND0612H, intended for severe Parkinson’s disease patients. The results indicate that ND0612H may provide an effective alternative therapy to current treatments requiring surgery.
Parkinson’s treatment trials success
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.